Anemia in chronic heart failure: Can we treat? What to treat?

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 203-210

  Von Haehling, Stephan ^a   Anker, Markus S ^b   Jankowska, Ewa A ^c   Ponikowski, Piotr ^c   Anker, Stefan D ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c MILITARY HOSPITAL   (Poland)

Author keywords

Anemia; Erythropoietin; Heart failure; Intravenous iron; Outcome; Symptoms

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

ANEMIA; COMORBIDITY; DISEASE CLASSIFICATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; IRON DEFICIENCY ANEMIA; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; HEART FAILURE; HEMATINICS; HUMANS; IRON; PROGNOSIS;

EID: 84862578773     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9283-x     Document Type: Review

References (52)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG) (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and ndorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933-989
2. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M, Boll H, Kim SS, Koehler K, Lücke S, Honold M, Heinze P, Schweizer T, Braecklein M, Kirwan BA, Gelbrich G, Anker SD (2010) TIM-HF Investigators. Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail 12:1354-1362
3. Lenk K, Schuler G, Adams V (2010) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachex Sarcopenia Muscle 1:9-21
4. von Haehling S, Doehner W, Anker SD (2007) Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73:298-309
5. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50:1561-1569
6. von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 1:1-5
7. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, van Veldhuisen DJ (2007) Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 9:787-794
8. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, Anker SD (2010) The effects of a highcaloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachex Sarcopenia Muscle 1:35-42
9. Okonko DO, Anker SD (2004) Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 10(1 Suppl):S5-S9
10. Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, van der Harst P, Vellenga E, van Veldhuisen DJ, van Gilst WH (2010) Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 12:676-684
11. Kleijn L, de Boer RA, Voors AA (2010) Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? Eur J Heart Fail 12:215-216
12. von Haehling S, Jankowska EA, Ponikowski P, Anker SD (2011) Anemia in heart failure: an overview of current concepts. Future Cardiol 7:119-129
13. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachex Sarcopenia Muscle 1:177-185
14. Braun TP, Marks DL (2010) Pathophysiology and treatment of inflammatory anorexia in chronic disease. J Cachex Sarcopenia Muscle 1:135-145
15. Beutler E, Waalen J (2006) The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 107:1747-1750
16. Goyette RE (1997) Hematology. A comprehensive guide to the diagnosis and treatment of blood disorders. Practice Management Information Cooperation (PMIC), Los Angeles
17. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S for the European Best Practice Guidelines Working Group (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl):Ii1-Ii47
18. Westenbrink BD, de Boer RA, Voors AA, van Gilst WH, van Veldhuisen DJ (2008) Anemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol 23:141-147
19. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR, Piepoli MF, Anker SD, Banasiak W, Ponikowski P (2003) Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90:303-308
20. Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41: 1933-1939
21. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and ResourceUtilization (ANCHOR)Study.Circulation 113:2713-2723
22. Adams KF Jr, Piña IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, Stough WG, Mehra MR, Felker GM, Chiong JR, Patterson JH, Kim J, Butler J, Oren RM (2009) Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 158: 965-971
23. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107:223-225
24. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011-1023
25. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461-473
26. Joosten E (2004) Strategies for the laboratory diagnosis of some common causes of anaemia in elderly patients. Gerontology 50: 49-56
27. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28:166-171
28. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26:2232-2237
29. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44:63-67
30. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818-827
31. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48:2485-2489
32. Macdougall IC (1999) Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 69:S61-S66
33. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, Roger SD, Savoia HF, Tampi R, Thomson AR, Wood EM, Robinson KL (2010) Diagnosis and management of iron deficiency anaemia: a clinical update. Med JAust 193:525-532
34. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P (2009) FAIR-HF committees and investigators. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic heart failure (FAIRHF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11:1084-1091
35. Danielson BG (2004) Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(Suppl):S93-S98
36. Auerbach M, Ballard H (2010) Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010:338-347
37. Anker SD, von Haehling S (2009) Anaemia in chronic heart failure. UNI-MED Verlag AG, Bremen
38. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) A peptide-based erythropoietinreceptor agonist for pure red-cell aplasia. N Engl J Med 361: 1848-1855
39. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744
40. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775-1780
41. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225-1227
42. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observerblinded trial. J Am Coll Cardiol 51:103-112
43. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436-2448
44. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P, FAIR-HF committees and investigators (2009) Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic heart failure (FAIRHF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11:1084-1091
45. Eschbach JW (2000) Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 20: 320-329
46. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228:1-14
47. Dicato M (2008) Venous thromboembolic events and erythropoiesis- stimulating agents: an update. Oncologist 13(Suppl 3): 11-15
48. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107:294-299
49. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49:753-762
50. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28: 2208-2216
51. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117:526-535
52. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB, RED-HF Committees and Investigators (2009) Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11:795-801